Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.

Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day.

Nov 7, 2024 · Moderna intends to file in 2024 for approval of its next-generation COVID-19 vaccine (mRNA-1283) and RSV vaccine (mRNA-1345) for high-risk adults aged 18-59; the Company expects to communicate the PDUFA date for each of …

Sep 12, 2024 · Looking ahead to 2026-2028, Moderna will expand its commercial portfolio with first-in-class vaccines and therapeutics to address non-respiratory diseases, including cytomegalovirus, norovirus, propionic acidemia, methylmalonic acidemia, and melanoma. Updates from Moderna's late-stage portfolio and approved vaccines include:

The mRNA DESIGN STUDIO integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput mRNA pre-clinical production facility manages the manufacturing of mRNA constructs and delivers them in just weeks.

Sep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.

Moderna's Mindsets “We believe our mRNA platform can solve the world’s greatest health challenges, from diseases impacting millions, to ultra-rare diseases impacting dozens, to medicines personalized down to the individual level.”

Moderna’s goal is to explore the potential of messenger RNA (mRNA) science to help create a new generation of medicines for patients.

Mar 26, 2024 · CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, …